Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meyer M Samama

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Clinical Chemistry and Laboratory Medicine|February 4, 2011
Laboratory assessment of new anticoagulantsMeyer M Samama, Céline Guinet
Current Opinion in Pulmonary Medicine|August 19, 2004
Prophylaxis of venous thromboembolism in medical patientsGrigoris T Gerotziafas, Meyer M Samama
Expert Review of Cardiovascular Therapy|July 1, 2004
Anticoagulant drugs: an updateHau C Kwaan, Meyer M Samama
Current Pharmaceutical Design|November 25, 2005
Heterogeneity of synthetic factor Xa inhibitorsGrigoris T Gerotziafas, Meyer M Samama
Thrombosis and Haemostasis|September 15, 2010
Does ambulation modify venous thromboembolism risk in acutely ill medical patients?Alpesh N Amin, Frederick Girard, Meyer M Samama
Chest|July 24, 2008
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jeffrey I Weitz, Jack Hirsh, Meyer M Samama
Thrombosis Research|September 3, 2014
Ex vivo reversal of the anticoagulant effects of edoxabanAbdel-Baset Halim, Meyer M Samama, Jeanne Mendell
Chest|September 24, 2004
New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyJeffrey I Weitz, Jack Hirsh, Meyer M Samama
La Revue Du Praticien|April 4, 2003
[Prevention of thrombo-embolic venous disease]Meyer-M Samama, Grigoris T Gerotziafas, Marie-Hélène Horellou
Thrombosis and Haemostasis|December 8, 2004
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profileGrigoris T Gerotziafas, Tahar Chakroun, Meyer M Samama, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Clinical Chemistry and Laboratory Medicine|February 4, 2011
Laboratory assessment of new anticoagulantsMeyer M Samama, Céline Guinet
Current Opinion in Pulmonary Medicine|August 19, 2004
Prophylaxis of venous thromboembolism in medical patientsGrigoris T Gerotziafas, Meyer M Samama
Expert Review of Cardiovascular Therapy|July 1, 2004
Anticoagulant drugs: an updateHau C Kwaan, Meyer M Samama
Current Pharmaceutical Design|November 25, 2005
Heterogeneity of synthetic factor Xa inhibitorsGrigoris T Gerotziafas, Meyer M Samama
Thrombosis and Haemostasis|September 15, 2010
Does ambulation modify venous thromboembolism risk in acutely ill medical patients?Alpesh N Amin, Frederick Girard, Meyer M Samama
Chest|July 24, 2008
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jeffrey I Weitz, Jack Hirsh, Meyer M Samama
Thrombosis Research|September 3, 2014
Ex vivo reversal of the anticoagulant effects of edoxabanAbdel-Baset Halim, Meyer M Samama, Jeanne Mendell
Chest|September 24, 2004
New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyJeffrey I Weitz, Jack Hirsh, Meyer M Samama
La Revue Du Praticien|April 4, 2003
[Prevention of thrombo-embolic venous disease]Meyer-M Samama, Grigoris T Gerotziafas, Marie-Hélène Horellou
Thrombosis and Haemostasis|December 8, 2004
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profileGrigoris T Gerotziafas, Tahar Chakroun, Meyer M Samama, et al.
Pageof 3